Sparfloxacin versus ciprofloxacin for the treatment of community- acquired, complicated skin and skin-structure infections

Clinical Therapeutics

Volumn 21, Issue 4, 1999, Pages 675-690

  Lipsky, Benjamin A ^a,i   Miller, Bruce ^b   Schwartz, Robert ^c   Henry, Dan C ^d   Nolan, Thomas ^e   McCabe, Ann ^f,h   Magner, David J ^f,g   Talbot, George H ^f  

^a UNIVERSITY OF WASHINGTON   (United States)

^b OREGON MEDICAL RESEARCH CENTER   (United States)

^c Associates in Research   (United States)

^d Foothill Family Clinic   (United States)

^e Baptist Health Center   (United States)

^f SANOFI   (France)

^g Astra Pharmaceuticals   (United States)

^h PAREXEL International/Barnett   (United States)

ⁱ VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

Anti infective agents; Complicated skin and skin structure infections; Fluoroquinolone; Sparfloxacin

Indexed keywords

CIPROFLOXACIN; SPARFLOXACIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; ERADICATION THERAPY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; PHOTOSENSITIVITY; PSEUDOMONAS AERUGINOSA; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; WOUND INFECTION;

EID: 0033051521     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)88319-8     Document Type: Article

References (24)

1. Failla DM, Pankey GA. Optimum outpatient therapy of skin and skin structure infections. Drugs. 1994;48:172-178.
2. Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. NEJM. 1996;334:240-245.
3. Gentry L. Therapy with newer oral β-lactam and quinolone agents for infections of the skin and skin structures: A review. Clin Infect Dis. 1992;14:285-297.
4. Gentry L. Review of quinolones in the treatment of infections of the skin and skin structure. J Antimicrob Chemother. 1991;28(Suppl C):97-110.
5. Baquero F, Canton R. In-vitio activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract pathogens. J Antimicrob Chemother. 1996;37(Suppl A):1-18.
6. Akiyama H, Torigoe R, Yamada T, et al. Sparfloxacin in the field of dermatology. Chemotherapy. 1991;39(S-4):145-148.
7. Yamamoto Y, Matsumoto S, Ikeda M, Kodama H. Penetration of sparfloxacin into the skin. Chemotherapy. 1991;39(S-4):741-742.
8. Nogita T, Ishibashi Y. The penetration of sparfloxacin into human plasma and skin tissues. J Antimicrob Chemother. 1991;28: 313-314.
9. Johnson JH, Cooper MA, Andrews JM, Wise R. Pharmacokinetics and inflammatory fluid penetration of sparfloxacin. Antimicrob Agents Chemother. 1992;36:2444-2446.
10. Parish LC, Jungkind DL. Systemic antimicrobial therapy in skin and skin structure infections: Comparison of temafloxacin and ciprofloxacin. Am J Med. 1991;91 (Suppl 6A);115S-119S.
11. Jaillon P, Morganroth J, Brumpt I, Talbot G. Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group. J Antimicrob Chemother. 1996;37(Suppl A):161-167.
12. Performance Standards for Antimicrobial Disk Susceptibility Tests. NCCLS Document M2-A5. Vol. 13, No. 24. 5th ed. Villanova, Pa: National Committee for Clinical Laboratory Standards; 1993.
13. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. NCCLS Document M7-A3. Vol. 13, No. 25. 3rd ed. Villanova, Pa: National Committee for Clinical Laboratory Standards; 1993.
14. Watanabe T, Akieda Y, Suzuki T, et al. Clinical trials of a new quinolone, sparfloxacin, in skin and skin structure infections. Drugs. 1993;45(Suppl 3):388-389.
15. Gentry L, Rodriguez-Gomez G, Zeluff B, et al. A comparative evaluation of oral ofloxacin versus intravenous cefotaxime for serious skin and skin structure infections. Am J Med. 1989;87(Suppl 6C):57-60.
16. Liu H, Bolash N, McAnany M, Lynch R. Susceptibility of bacterial isolates from complicated skin and skin structure infections to cefazolin, imipenem-cilastatin, ciprofloxacin and ofloxacin. Drugs. 1995; 49(Suppl 2):215-218.
17. Tack K, Littlejohn T, Mailloux G, et al. Cefdinir versus cephalexin for the treatment of skin and skin-structure infections. The Cefdinir Adult Skin Infection Study Group. Clin Ther. 1998;20:244-256.
18. Rubinstein E. Safety profile of sparfloxacin in the treatment of respiratory tract infections. J Antimicrob Chemother. 1996; 37(Suppl A):145-160.
19. Speciale A, Blandino G, Nicolosi VM, et al. Bactericidal kinetics and postantibiotic effect of sparfloxacin against selected species of respiratory pathogens. J Chemother. 1995;7:530-534.
20. Von Rosensteil N, Adam D. Quinolone antibacterials. An update of their pharmacology and therapeutic use. Drugs. 1994; 47:872-901.
21. Lipsky BA, Dorr MB, Magner DJ, Talbot GH. Safety profile of sparfloxacin, a new fluoroquinolone antibiotic. Clin Ther. 1999; 21:148-159.
22. DeAbate CA, Henry D, Bensch G, et al. Sparfloxacin versus ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis: A multicenter, double-blind, randomized, comparative study. Sparfloxacin Multicenter ABECB Study Group. Chest. 1998;114:120-130.
23. Henry D, Ellison W, Sullivan J, et al. Treatment of community-acquired acute uncomplicated urinary tract infection with sparfloxacin versus ofloxacin. The Sparfloxacin Multicenter UUTI Study Group. Antimicrob Agents Chemother. 1998;42: 2262-2266.
24. Lietman PS. Fluoroquinolone toxicities: An update. Drugs. 1995;42(Suppl 2):159-163.